MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2018 International Congress

    Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2

    R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, USA)

    Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…
  • 2018 International Congress

    Rapamycin for treating MSA: A preclinical proof of concept study

    M. Lopez-Cuina, P. Guerin, E. Bezard, W. Meissner, P-O. Fernagut (Bordeaux, France)

    Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…
  • 2018 International Congress

    Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synuclenopathies

    I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, M.M. Carmona-Abellan, I. Marcilla-Garcia, L. Alonso-Herrero, G. Marti-Andres, T. Tuñon-Alvarez, M.R. Luquin-Piudo (Pamplona, Spain)

    Objective: We have investigated whether deposits of phosphorylated α-synuclein might be present in pancreatic tissue of subjects with synucleinopathies. Background: Parkinson’s disease patients experience a…
  • 2018 International Congress

    Effects of Glial Heme Oxygenase-1 on Neuronal Alpha-Synuclein in the GFAP.HMOX1 Mouse Model of Parkinson’s Disease

    M. Cressatti, W. Song, A. Turk, C. Galindez, H. Schipper (Montreal, QC, Canada)

    Objective: To determine whether astroglial HO-1 transduces environmental and endogenous stressors into patterns of neural damage which promote the toxicity of neuronal alpha-synuclein. Background: The…
  • 2018 International Congress

    The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease

    D. Price, M. Koike, W. Wrasidlo, A. Khan, E. Rockenstein, E. Masliah, D. Bonhaus (San Diego, CA, USA)

    Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…
  • 2018 International Congress

    PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy

    D. Finkelstein, P. Adlard, N. Stefanova, D. Stamler (Parkville, Vic, Australia)

    Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…
  • 2018 International Congress

    Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy

    G. Vivacqua, A. Fabbrini, R. Mancinelli, D. Belvisi, G. Fabbrini, A. Suppa, A. Berardelli (Cambridge, United Kingdom)

    Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…
  • 2018 International Congress

    Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

    G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

    Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…
  • 2018 International Congress

    A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design

    T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Chicago, IL, USA)

    Objective: To assess the safety and tolerability of nilotinib (150-300 mg QD) in moderate/advanced and early/de novo Parkinson disease (PD) participants. Background: Studies in cell…
  • 2018 International Congress

    Possible neurotoxic hazards of common adulterants in Tea among Drosophila; ascertainment of toxicity of Tea preparations from local shops of an Indian city

    C. Ratnakaran, G. Chandran (Bengaluru, India)

    Objective: The present study assesses the neurotoxic implications of common adulterants of Tea in drosophila system in terms of tremor behaviour and neurochemical changes. Also…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley